Log in or register to see all Alerts
New HTA Decisions in France
June 2020
Drug name
NEXAVAR® (sorafenib)
Company
Bayer HealthCare SAS
Decision date
23/10/2019
Therapeutic area
Cancer
Therapeutic sub area
Renal cancer
Official notice date
25/11/2019
Reimbursement %
Decision (SMR)
Insufficient to justify reimbursement
Decision (ASMR)
Indication
NEXAVAR® is indicated for the treatment of advanced renal cell carcinoma after failure of prior treatment with interferon alfa or interleukin-2 or in patients for whom these therapies are considered unsuitable.
Decision Type
Reassessment of SMR and ASMR.
Summary
The committee considered the actual benefit of NEXAVAR® to be insufficient to justify reimbursement in the indication of the Marketing Authorisation with regard to the current treatment.